Armata Pharmaceuticals, Inc.
ARMP- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000921114
No open-market purchases or sales by Armata Pharmaceuticals, Inc. insiders were filed in the last 90 days; 53 institutions reported holding it in 13F filings for Q2 2026, worth $32.3M in total; no superinvestor holds it.
13F holders, Q1 2024
Institutional positions in Armata Pharmaceuticals, Inc. as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 24
- −1 vs. Q4 2023
- Shares held
- 1.42M
- +130.7K (+10.1%) vs. Q4 2023
- Total value
- $5.93M
- +$1.76M (+42.2%) vs. Q4 2023
- New holders
- 2
- 7 more added
- Sold out
- 3
- 8 more reduced
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ARMP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 53 | $32.3M |
| Q1 2026 | 45 | $40.2M |
| Q4 2025 | 36 | $7.85M |
| Q3 2025 | 28 | $2.27M |
| Q2 2025 | 29 | $1.40M |
| Q1 2025 | 26 | $1.08M |
| Q4 2024 | 24 | $2.57M |
| Q3 2024 | 24 | $3.28M |
| Q2 2024 | 23 | $3.86M |
| Q1 2024 | 24 | $5.93M |
| Q4 2023 | 25 | $4.17M |
| Q3 2023 | 23 | $3.85M |
| Q2 2023 | 22 | $1.35M |
| Q1 2023 | 23 | $2.06M |
| Q4 2022 | 26 | $1.61M |
| Q3 2022 | 20 | $5.73M |
| Q2 2022 | 19 | $5.25M |
| Q1 2022 | 20 | $6.61M |
| Q4 2021 | 17 | $7.25M |
| Q3 2021 | 20 | $4.32M |
| Q2 2021 | 21 | $4.59M |
| Q1 2021 | 23 | $5.62M |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding Armata Pharmaceuticals, Inc.; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bank of America Corp | 636,638 | $2.66M | 0.00% | +2,187+0.3% | Added |
| Vanguard Group Inc | 159,209 | $665.5K | 0.00% | +14,131+9.7% | Added |
| Bridgeway Capital Management, LLC | 110,382 | $461.4K | 0.01% | 00.0% | Unchanged |
| Edgewood Management LLC | 100,000 | $418.0K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 99,888 | $417.6K | 0.00% | −1,125−1.1% | Reduced |
| Susquehanna International Group, LLP | 87,803 | $367.0K | 0.00% | +87,803 | New |
| Renaissance Technologies LLC | 51,396 | $215.0K | 0.00% | −2,200−4.1% | Reduced |
| State Street Corp | 40,300 | $168.5K | 0.00% | 00.0% | Unchanged |
| SeaCrest Wealth Management, LLC | 32,777 | $137.0K | 0.02% | +14,647+80.8% | Added |
| BlackRock Inc. | 23,868 | $99.8K | 0.00% | +1,108+4.9% | Added |
| Qube Research & Technologies Ltd | 22,414 | $93.7K | 0.00% | −1,149−4.9% | Reduced |
| Northern Trust Corp | 19,292 | $80.6K | 0.00% | −88−0.5% | Reduced |
| Citadel Advisors LLC | 17,965 | $75.1K | 0.00% | +17,965 | New |
| Captrust Financial Advisors | 13,140 | $54.9K | 0.00% | −408−3.0% | Reduced |
| Tower Research Capital LLC (TRC) | 1,697 | $7.09K | 0.00% | −1,670−49.6% | Reduced |
| UBS Group AG | 767 | $3.21K | 0.00% | +766+76,600.0% | Added |
| Trifecta Capital Advisors, LLC | 714 | $2.98K | 0.00% | 00.0% | Unchanged |
| Northwestern Mutual Wealth Management Co | 571 | $2.39K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 426 | $1.78K | 0.00% | +424+21,200.0% | Added |
| Householder Group Estate & Retirement Specialist, LLC | 136 | $568 | 0.00% | 00.0% | Unchanged |
| Salem Investment Counselors Inc | 100 | $418 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 86 | $357 | 0.00% | +2+2.4% | Added |
| JPMorgan Chase & Co | 26 | $109 | 0.00% | −79−75.2% | Reduced |
| Royal Bank of Canada | 26 | $0 | 0.00% | −256−90.8% | Reduced |
| Larson Financial Group LLC | 0 | $0 | 0.00% | −967−100.0% | Sold out |
| Tennessee Valley Asset Management Partners | 0 | $0 | 0.00% | −279−100.0% | Sold out |
| Team Financial Group, LLC | 0 | $0 | 0.00% | −71−100.0% | Sold out |